Right Heart Failure Clinical Trial
Official title:
A Prospective, Multicenter, Observational, Investigator Initiated Study, Aiming at Serial Multiparametric Evaluation of Right Ventricular Function to Predict Optimal Management Strategies, of Right Heart Failure After LVAD Implantation
The primary purpose of this study is to investigate the evolution of Right Ventricular (RV)
function before and after left ventricular assist device (LVAD) implantation, using novel
echocardiographic quantification of RV size and function in combination with comprehensive
hemodynamic, laboratory and clinical parameters. The findings of the study will enhance
prediction of early and late development of postoperative right-sided heart failure (RHF) and
subsequent mortality and morbidity.
The secondary purpose of the study is to combine echocardiographic, hemodynamic, laboratory,
and clinical data to define optimal management strategies of RHF after LVAD implantation.
The study consists of 2 parts: a Pilot study and a Main Study as detailed below.
The purpose of the Pilot study is to evaluate the feasibility of RV quantification using
two-, three-dimensional and Multiplane echocardiography.
About 100 subjects undergoing LVAD implantation in the European Registry for Patients with
Mechanical Circulatory Support (EUROMACS) Registry are included in the Pilot study. These 100
patients will undergo routinely scheduled echocardiography before, within 1 week, 3 months
and 1 year after LVAD implantation. Echocardiography will be performed using ultrasound
machines that are capable of acquisition of two-, three-dimensional and Multiplane
Echocardiography of the right ventricle.
Echocardiographic analysis will include three-dimensional quantification of the RV size and
function as well as RV strain analysis in the Multiplane format as described in the Appendix
Echocardiography Procedure Manual.
The Echocardiographic analyses of the first 50 patients, included in selected sites, will be
used to further specify the protocol for image acquisition and analysis to be used in the
Main Study. Furthermore, all sites will first enter 2 patients in the Pilot Study before they
can participate in the Main Study. The echocardiographic results of these 2 patients will be
assessed by the core lab for quality.
The purpose of the Main Study is to assess the evolution of RV function before and after LVAD
implantation utilizing the acquisition and analysis protocol developed in the Pilot Study.
500 patients will undergo routinely scheduled echocardiographic imaging before LVAD
implantation, and at 1 week, 1 month, 3 months, 6 months and 1 year thereafter.
Echocardiography will be performed using the detailed protocol developed in the Pilot Study.
All Echocardiographic images will be submitted to an independent Core Laboratory for
analysis.
The evolution of RV function will be documented with standardised two-, three-dimensional and
Multiplane Echocardiography of the right ventricle. The echocardiographic parameters include:
RV strain and strain rate, RV Fractional Area Change, RV longitudinal function, RV volumes,
RV ejection fraction, tricuspid regurgitation severity, estimated pulmonary artery pressures,
pulmonary artery resistance, pulmonary artery compliance, RV stroke work index, right atrial
size, and RV - pulmonary coupling.
Invasive hemodynamic data will be collected in the perioperative period. These RV parameters
will be linked to the occurrence of clinical signs, hemodynamic and laboratory evidence of
RHF.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05948332 -
Definition and Management of Right Ventricular Injury in Adult Patients Receiving Extracorporeal Membrane Oxygenation
|
||
Not yet recruiting |
NCT06002321 -
Right Ventricular Dysfunction in Chronic Heart Failure
|
||
Not yet recruiting |
NCT06039176 -
Human/Machine Interface: What the HeartMate 3 ® Device Tells Us About the Future
|
||
Completed |
NCT03438825 -
PRediction of Early PostoperAtive Right vEntricular Failure in Mitral Valve Replacement/Repair Patients
|
||
Recruiting |
NCT05179616 -
Pforzheim Tricuspid Valve Registry - Outcomes of Percutaneous Tricuspid Valve Repair
|
||
Completed |
NCT02644616 -
The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves Replacement
|
Phase 4 | |
Completed |
NCT03656263 -
The Clinical Significance of Portal Hypertension After Cardiac Surgery: a Multicenter Prospective Observational Study
|
||
Recruiting |
NCT01777607 -
The Use of Impella RP Support System in Patients With Right Heart Failure
|
N/A | |
Completed |
NCT03554291 -
Repurposing a Histamine Antagonist to Benefit Patients With Pulmonary Hypertension
|
Phase 2 | |
Completed |
NCT03217331 -
CRD-102 for Right Heart Failure in Patients With Left Ventricular Assist Devices
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT00834145 -
Effect of Normatec Pump for Relief of Leg Edema in Patients With Right Heart Failure
|
N/A | |
Recruiting |
NCT03202641 -
Open Lung Strategy, Gas Distribution and Right Heart Function in ARDS Patients
|
N/A | |
Not yet recruiting |
NCT05450328 -
Inhaled Milrinone and Epoprostenol for the Prevention of Difficult Cardiac Pulmonary Bypass Separation
|
Phase 2 | |
Not yet recruiting |
NCT04188756 -
RV Systolic and Diastolic Function and Contractile Reserve Under Acute Exercise and in Response to Chronic Exercise-based Rehabilitation
|
N/A | |
Completed |
NCT01757522 -
Detection of Right Ventricular Dysfunction by 2D Strain During Acute Respiratory Distress Syndrom (ARDS)
|
||
Withdrawn |
NCT00811486 -
Body Volume Regulation in Pulmonary Arterial Hypertension With Right Ventricular Failure
|
N/A | |
Completed |
NCT05366400 -
Relationship Between Right Atrial Volume Index, Functional Capacity and Inflammatory Biomarkers in Patients With COPD.
|
||
Terminated |
NCT03073629 -
Assessing Outcomes in ED Patients With RV Failure
|
N/A | |
Active, not recruiting |
NCT06023134 -
Clinical Characteristics and Outcomes of Patients With Pulmonary Hypertension Associated Right Heart Failure
|
||
Recruiting |
NCT06053580 -
Repurposing Valsartan May Protect Against Pulmonary Hypertension
|
Phase 2 |